About Protein mono-ADP-ribosyltransferase PARP9
Protein mono-ADP-ribosyltransferase PARP9 (PARP9) is a protein
from Homo sapiens identified by UniProt accession
Q8IXQ6, 854 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | Protein mono-ADP-ribosyltransferase PARP9 |
|---|
| UniProt accession | Q8IXQ6 |
|---|
| Gene | PARP9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 854 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (108)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.37
- severe acute respiratory syndrome · score 0.37
- calcium measurement · score 0.23
- mean corpuscular volume · score 0.23
- low density lipoprotein cholesterol measurement · score 0.22
- neurodegenerative disease · score 0.22
- total cholesterol measurement · score 0.21
- apolipoprotein B measurement · score 0.19
- diastolic blood pressure · score 0.16
- HbA1c measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IXQ6-F1 | alphafold | PREDICTED | 78.74 | — |
Amino-acid sequence (854 residues)
MDFSMVAGAA AYNEKSGRIT SLSLLFQKVF AQIFPQWRKG NTEECLPYKC SETGALGENY SWQIPINHND FKILKNNERQ LCEVLQNKFG CISTLVSPVQ EGNSKSLQVF RKMLTPRIEL SVWKDDLTTH AVDAVVNAAN EDLLHGGGLA LALVKAGGFE IQEESKQFVA RYGKVSAGEI AVTGAGRLPC KQIIHAVGPR WMEWDKQGCT GKLQRAIVSI LNYVIYKNTH IKTVAIPALS SGIFQFPLNL CTKTIVETIR VSLQGKPMMS NLKEIHLVSN EDPTVAAFKA ASEFILGKSE LGQETTPSFN AMVVNNLTLQ IVQGHIEWQT ADVIVNSVNP HDITVGPVAK SILQQAGVEM KSEFLATKAK QFQRSQLVLV TKGFNLFCKY IYHVLWHSEF PKPQILKHAM KECLEKCIEQ NITSISFPAL GTGNMEIKKE TAAEILFDEV LTFAKDHVKH QLTVKFVIFP TDLEIYKAFS SEMAKRSKML SLNNYSVPQS TREEKRENGL EARSPAINLM GFNVEEMYEA HAWIQRILSL QNHHIIENNH ILYLGRKEHD ILSQLQKTSS VSITEIISPG RTELEIEGAR ADLIEVVMNI EDMLCKVQEE MARKKERGLW RSLGQWTIQQ QKTQDEMKEN IIFLKCPVPP TQELLDQKKQ FEKCGLQVLK VEKIDNEVLM AAFQRKKKMM EEKLHRQPVS HRLFQQVPYQ FCNVVCRVGF QRMYSTPCDP KYGAGIYFTK NLKNLAEKAK KISAADKLIY VFEAEVLTGF FCQGHPLNIV PPPLSPGAID GHDSVVDNVS SPETFVIFSG MQAIPQYLWT CTQEYVQSQD YSSGPMRPFA QHPWRGFASG SPVD
Explore Protein mono-ADP-ribosyltransferase PARP9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets